Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
Sponsor: University of California, San Diego
Summary
The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested
Key Details
Gender
All
Age Range
50 Years - 83 Years
Study Type
INTERVENTIONAL
Enrollment
53
Start Date
2019-01-31
Completion Date
2025-12-30
Last Updated
2026-01-07
Healthy Volunteers
No
Conditions
Interventions
Memantine
Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this "challenge" test, a set of "early auditory information processing memantine sensitivity" measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated.
Locations (1)
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center
San Diego, California, United States